Loading...
XASE
SDEV
Market cap36mUSD
Jul 06, Last price  
1.38USD
1D
1.47%
1Q
-18.82%
Jan 2017
-100.00%
IPO
-100.00%
Name

NovaBay Pharmaceuticals Inc

Chart & Performance

D1W1MN
XASE:SDEV chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
109.81%
Rev. gr., 5y
8.19%
Revenues
0k
-100.00%
1,533,0005,913,0006,722,00015,684,0009,754,00011,019,0006,947,0003,477,0001,054,0004,381,00011,897,00018,230,00012,508,0006,599,0009,934,00010,204,00014,404,00010,455,0009,781,0000
Net income
-22m
L+206.53%
-5,286,000-5,400,000-8,114,0002,697,000-4,308,000-5,085,000-7,027,000-16,042,000-15,194,000-18,973,000-13,151,000-7,403,000-6,545,000-9,658,000-11,039,000-5,824,000-10,608,000-9,640,000-7,223,000-22,141,000
CFO
-8m
L+62.65%
4,744,000-6,271,000-9,942,000-1,648,0002,028,000-3,142,000-6,528,000-12,969,000-15,055,000-18,559,000-12,135,000-6,270,000-5,568,000-7,929,000-4,721,000-9,192,000-6,654,000-4,261,000-5,183,000-8,430,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.
URL
https://novabay.com/
IPO date
Oct 26, 2007
Employees
29
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT